Khiron Life Sciences Corp. (KHRNF)
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
KHRNF steht fuer Khiron Life Sciences Corp., ein Healthcare-Unternehmen mit einem Kurs von $ (Marktkapitalisierung 0). Die Aktie erzielt 59/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 16. März 2026Khiron Life Sciences Corp. (KHRNF) Gesundheitswesen & Pipeline-Uebersicht
Khiron Life Sciences Corp. is an integrated medical cannabis company operating in Latin America and Europe. It distinguishes itself through its cultivation, production, and distribution of medical cannabis, coupled with a network of health centers and CBD-based cosmeceutical products, positioning it within the evolving global cannabis market.
Investmentthese
Khiron Life Sciences Corp. presents an investment opportunity within the expanding medical cannabis market in Latin America and Europe. The company's integrated business model, encompassing cultivation, production, distribution, and clinic operations, offers potential for revenue diversification and market penetration. A key value driver is the increasing acceptance and legalization of medical cannabis in target markets, which could drive demand for Khiron's products and services. Growth catalysts include expanding the network of Zerenia clinics and developing new CBD-based products. However, potential risks include regulatory uncertainties, competition from other cannabis companies, and the company's current negative profit margin of -258.9%. Investors should monitor the company's ability to achieve profitability and navigate the evolving regulatory landscape.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Operates in the rapidly growing medical cannabis market in Latin America and Europe.
- Integrated business model encompassing cultivation, production, distribution, and clinic operations.
- Gross margin of 22.5% indicates potential for profitability with increased scale.
- Network of health centers and satellite clinics under the ILANS and Zerenia brands provides a direct channel to patients.
- Development of CBD-based cosmeceutical products under the Kuida brand diversifies revenue streams.
Wettbewerber & Vergleichsunternehmen
Staerken
- Integrated business model.
- Established presence in Latin America and Europe.
- Network of health centers and satellite clinics.
- Development of CBD-based cosmeceutical products.
Schwaechen
- Negative profit margin.
- Limited financial resources.
- Dependence on regulatory approvals.
- Intense competition.
Katalysatoren
- Upcoming: Expansion of Zerenia clinic network to new locations in Latin America and Europe.
- Ongoing: Increasing legalization and acceptance of medical cannabis in target markets.
- Ongoing: Development and launch of new CBD-based products.
- Ongoing: Strategic partnerships with pharmaceutical companies and healthcare providers.
- Upcoming: Securing regulatory approvals for medical cannabis products in new countries.
Risiken
- Potential: Regulatory uncertainties and changes in cannabis laws.
- Ongoing: Competition from established pharmaceutical companies and other cannabis companies.
- Potential: Fluctuations in cannabis prices and supply chain disruptions.
- Ongoing: Negative profit margin and limited financial resources.
- Potential: Economic downturns and reduced consumer spending.
Wachstumschancen
- Expansion of Zerenia Clinics: Khiron can expand its network of Zerenia clinics across Latin America and Europe. Each new clinic increases patient access to medical cannabis treatments, driving revenue growth. The medical cannabis market in Latin America is projected to grow significantly, offering a substantial opportunity for Khiron to capture market share through clinic expansion. Timeline: Ongoing.
- Development of New CBD Products: Khiron can develop and launch new CBD-based products, including cosmeceuticals and wellness products. The global CBD market is experiencing rapid growth, driven by increasing consumer awareness of the potential health benefits of CBD. This presents a significant opportunity for Khiron to diversify its revenue streams and expand its customer base. Timeline: Ongoing.
- Strategic Partnerships: Khiron can form strategic partnerships with pharmaceutical companies, research institutions, and healthcare providers to expand its reach and access new markets. Partnerships can provide access to new technologies, distribution channels, and patient populations. This can accelerate Khiron's growth and enhance its competitive position. Timeline: Ongoing.
- Regulatory Approvals: Securing regulatory approvals for its medical cannabis products in new markets can drive significant revenue growth for Khiron. As more countries legalize medical cannabis, Khiron can expand its geographic footprint and access new patient populations. This requires navigating complex regulatory processes and demonstrating the safety and efficacy of its products. Timeline: Ongoing.
- International Exports: Khiron can increase its exports of medical cannabis products to international markets. The global medical cannabis market is expanding rapidly, creating opportunities for Khiron to supply its products to countries with limited domestic production capacity. This requires establishing international distribution networks and complying with export regulations. Timeline: Ongoing.
Chancen
- Expansion of Zerenia clinics.
- Development of new CBD products.
- Strategic partnerships.
- International exports.
Risiken
- Regulatory uncertainties.
- Competition from established pharmaceutical companies.
- Fluctuations in cannabis prices.
- Economic downturns.
Wettbewerbsvorteile
- Integrated business model encompassing cultivation, production, distribution, and clinic operations.
- Established network of health centers and satellite clinics.
- Brand recognition in Latin America and Europe.
- Expertise in cultivating and producing high-quality medical cannabis.
Ueber KHRNF
Khiron Life Sciences Corp., established in 2012 and headquartered in Vancouver, Canada, operates as an integrated medical cannabis company with a focus on Latin America and Europe. The company's business is structured around three segments: Health Services, Medical Cannabis Products, and Wellbeing Products. Khiron cultivates, produces, distributes, and exports tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. The company has established a network of health centers and satellite clinics under the ILANS and Zerenia brands, providing medical cannabis consultations and treatments. Additionally, Khiron develops and markets CBD-based cosmeceutical products under the Kuida brand. Its operations include a Zerenia clinic in Medellin, Colombia, and Peru, expanding access to medical cannabis treatments in the region. Khiron aims to establish itself as a leader in the Latin American and European medical cannabis markets by integrating cultivation, production, distribution, and patient care.
Was das Unternehmen tut
- Cultivates and produces medical cannabis.
- Distributes and exports medical cannabis products.
- Operates a network of health centers and satellite clinics under the ILANS and Zerenia brands.
- Develops CBD-based cosmeceutical products under the Kuida brand name.
- Provides medical cannabis consultations and treatments.
- Operates Zerenia clinics in Medellin and Peru.
Geschaeftsmodell
- Cultivation and production of medical cannabis.
- Distribution and sale of medical cannabis products through clinics and other channels.
- Provision of medical consultations and treatments at Zerenia clinics.
- Sale of CBD-based cosmeceutical products.
Branchenkontext
Khiron Life Sciences Corp. operates in the burgeoning medical cannabis industry, which is experiencing significant growth due to increasing legalization and acceptance of cannabis for medical purposes. The global medical cannabis market is projected to reach billions of dollars in the coming years. Khiron competes with other cannabis companies, including ANTCF (Antibe Therapeutics Inc.), BSPK (Bioscience Properties Inc.), EVIO (EVIO Inc.), GENPF (General Cannabis Corp), and HEMP (HEMP, Inc.), as well as established pharmaceutical companies exploring cannabis-based treatments. Khiron's focus on Latin America and Europe differentiates it from competitors primarily focused on North America.
Wichtige Kunden
- Patients seeking medical cannabis treatments.
- Consumers of CBD-based cosmeceutical products.
- Healthcare providers prescribing medical cannabis.
- Distributors of medical cannabis products.
Finanzdaten
Chart & Info
Khiron Life Sciences Corp. (KHRNF) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
Stocks That Hit 52-Week Lows On Friday
· 28. Feb. 2020
-
Stocks That Hit 52-Week Lows On Thursday
· 27. Feb. 2020
-
Stocks That Hit 52-Week Lows On Wednesday
· 26. Feb. 2020
-
Stocks That Hit 52-Week Lows On Friday
· 8. Nov. 2019
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer KHRNF.
Kursziele
Wall-Street-Kurszielanalyse fuer KHRNF.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von KHRNF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Wettbewerber & Vergleichsunternehmen
Fuehrung: Alvaro Francisco Torres
CEO
Alvaro Francisco Torres serves as the CEO of Khiron Life Sciences Corp. His background includes experience in the healthcare and pharmaceutical industries. He has a proven track record of leading and growing companies in emerging markets. His expertise spans strategic planning, business development, and operational management. He is responsible for overseeing all aspects of Khiron's business, including cultivation, production, distribution, and clinic operations.
Erfolgsbilanz: Under Alvaro Francisco Torres' leadership, Khiron Life Sciences Corp. has expanded its operations in Latin America and Europe, established a network of Zerenia clinics, and developed CBD-based cosmeceutical products. He has overseen the company's efforts to secure regulatory approvals for its medical cannabis products in various countries. His strategic decisions have positioned Khiron as a leader in the Latin American medical cannabis market.
KHRNF OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Khiron Life Sciences Corp. may not meet the minimum financial standards or reporting requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading can be more speculative. This tier is often populated by shell companies, companies in bankruptcy, or those unwilling or unable to meet the requirements of higher tiers. Investors should exercise caution and conduct thorough due diligence before investing in companies on the OTC Other tier.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited disclosure and transparency due to the OTC Other tier listing.
- Higher price volatility due to lower trading volumes and liquidity.
- Potential for fraudulent or manipulative activities.
- Lack of regulatory oversight compared to major exchanges.
- Difficulty in obtaining reliable information about the company's financial performance.
- Verify the company's registration and legal status.
- Review the company's financial statements, if available.
- Assess the company's management team and their experience.
- Research the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Operations in the regulated medical cannabis industry.
- Network of health centers and satellite clinics under established brands.
- Development of CBD-based cosmeceutical products.
- Presence in Latin America and Europe.
- CEO with experience in the healthcare and pharmaceutical industries.
Khiron Life Sciences Corp. Aktie: Wichtige Fragen beantwortet
What are the key factors to evaluate for KHRNF?
Khiron Life Sciences Corp. (KHRNF) currently holds an AI score of 59/100, indicating moderate score. Key strength: Integrated business model.. Primary risk to monitor: Potential: Regulatory uncertainties and changes in cannabis laws.. This is not financial advice.
How frequently does KHRNF data refresh on this page?
KHRNF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven KHRNF's recent stock price performance?
Recent price movement in Khiron Life Sciences Corp. (KHRNF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Integrated business model.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider KHRNF overvalued or undervalued right now?
Determining whether Khiron Life Sciences Corp. (KHRNF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying KHRNF?
Before investing in Khiron Life Sciences Corp. (KHRNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding KHRNF to a portfolio?
Potential reasons to consider Khiron Life Sciences Corp. (KHRNF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Integrated business model.. Additionally: Established presence in Latin America and Europe.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of KHRNF?
Yes, most major brokerages offer fractional shares of Khiron Life Sciences Corp. (KHRNF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track KHRNF's earnings and financial reports?
Khiron Life Sciences Corp. (KHRNF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for KHRNF earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available company data and may be subject to change.
- OTC market data may be less reliable than data from major exchanges.